On September 17 th 2012, the Intellectual Property Appellate Board (IPAB) dismissed Bayer’s request for a stay order against the Compulsory License (CL) granted by the Patent Controller on March 9, 2012 to Natco for Nexavar, a drug to treat renal cell and hepato-cellular carcinoma (cancer). Bayer in its appeal before the IPAB had said that the CL decision of the Indian Patent Controller is illegal and unsustainable, and had filed for an immediate stay during the pendency of the appeal. This decision of IPAB comes as a relief to the patients who will now be able to have this drug at a far cheaper rate than being offered by German pharmaceutical major Bayer.